Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.49 |
| ▸ | HTR2C | P28335 | 3/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 4/20 | 0.43 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.43 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.43 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.43 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 6/20 | 0.43 |
| ▸ | KIF11 | P52732 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | NPY1R | P25929 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11328019 | 0.85 | CA2 (0.47) | HSD11B1KIF11HTR6 | |
| SCHEMBL8174103 | 0.82 | GAA (0.52) | KIF11HTR6 | |
| SCHEMBL4618091 | 0.81 | FFAR4 (0.49) | HSD11B1KIF11HTR6 | |
| SCHEMBL4617893 | 0.81 | HSD11B1 (0.48) | HSD11B1HTR2CHTR2BCNR1ABCC9 | |
| SCHEMBL4617928 | 0.79 | KMT2A (0.54) | HSD11B1HTR2CHTR2BCNR1ABCC9 | |
| SCHEMBL4617436 | 0.78 | FFAR4 (0.51) | HSD11B1HTR2CHTR2BABCC9ABCC8 | |
| SCHEMBL8866512 | 0.74 | HTR6 (0.59) | HSD11B1HTR2CHTR2BCNR1ABCC9 | |
| SCHEMBL11326348 | 0.73 | FFAR4 (0.48) | HSD11B1KIF11HTR6 | |
| SCHEMBL4617109 | 0.73 | HSD11B1 (0.52) | HSD11B1ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL11325999 | 0.73 | KIF11 (0.43) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879859-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2006124875-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | WYETH (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | SFRP1, SOS1, FZD7 | HSD11B1 205/4885HTR2C 3668/4885HTR2B 3802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.